Company Cancer Prevention Pharmaceuticals Inc

Cancer Prevention Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutic agents for the treatment and prevention of certain pre-cancerous conditions, orphan diseases and gastrointestinal conditions. Its investigational drug product, CPP-1X/sul, is a combination of the polyamine synthesis inhibitor CPP-1X and the non-steroidal anti-inflammatory drug sulindac. Its product pipeline includes CPP-1X/sul and CPP-1X. It is engaged in enrolling patients in its Phase III clinical trial with its product candidate, CPP-1X/sul, for the treatment of familial adenomatous polyposis (FAP). CPP-1X/sul, which is used for treating colon cancer risk reduction, is in Phase III clinical trial. It has completed Phase I clinical trial for CPP-1X in treating gastric cancer. CPP-1X is in Phase II clinical trial for the treatment of neuroblastoma, and in Phase I clinical trial for the treatment of early onset type 1 diabetes.